ARPA-H Bets $62.7 Million on the First FDA-Authorized Heart-Failure AI Agent

Primary source: ARPA-H — ADVOCATE program announcement (September 9, 2026).

ARPA-H bets $62.7 million on the first FDA-authorized heart-failure AI agent

The Advanced Research Projects Agency for Health (ARPA-H) has named the teams receiving contract awards under its Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program. The stated goal: create the world’s first reliable, FDA-authorized patient-facing clinical agentic AI for heart failure — a 24/7 digital member of the clinical care team.

ARPA-H’s commitment is a four-year, $62.7 million program with up to $33.7 million in year one. That is funded work with a regulatory clock — not an FDA authorization today. TA1 performers must submit a first-of-its-kind FDA authorization package within 24 months of award.

Context from the announcement: cardiovascular disease remains the leading U.S. killer; more than 200,000 Americans die each year from preventable CVD impacts; nearly half of U.S. counties have no cardiologist. ARPA-H estimates that if ADVOCATE succeeds, it could generate about $28 billion in annual cost savings across the heart failure population alone — an agency projection, not a proven outcome.

Who ships what — TA1, TA2, and TA3

TA1 — patient-facing clinical AI agents (FDA authorization package due within 24 months of award):

• Atman Health — evidence-based clinical decision engine plus LLMs with a voice-first interface that adapts diagnostic questions in conversation.
• Tempus AI — extends the existing Olivia patient health app with continuous monitoring and deeper clinical analysis when meaningful changes are detected.
• UpDoc — separates conversational intelligence from clinical authority via a clinician-built rules system that validates every proposed action against approved protocols before execution.

TA2 — supervisory AI: Stanford University builds a disease-agnostic supervisory system (outlier filtering, rule-based screening, deep-research auditing agent) meant to monitor TA1 agents after deployment and surface inspectable per-claim rationales.

TA3 — scalable implementation:

• Duke University — multi-site validation across five health systems plus rural sites on Epic and Cerner/Oracle EHRs, amplified by American Heart Association reach.
• Kaiser Permanente — enterprise-scale path across 21 medical centers and 260+ clinics, embedding agents into Epic workflows for heart failure patients, with shadow-mode deployments and pragmatic randomized clinical trials.

Independent evaluator: Johns Hopkins University Applied Physics Laboratory (JHU/APL). The FDA Digital Health Center of Excellence is engaged on the regulatory framework for this class of patient-facing clinical AI.

What this proves — and what it does not

Proves (so far):

• ARPA-H has awarded a named, multi-track program (ADVOCATE) with public performers across patient-facing agents, supervisory AI, and health-system implementation.
• There is an explicit FDA engagement path and a hard clock: TA1 must submit an authorization package within 24 months of award.
• Named health systems (Duke network sites; Kaiser Permanente) and an independent evaluator (JHU/APL) are on the record.

Does not prove:

• That any ADVOCATE agent is FDA-authorized today — the package deadline is not authorization.
• That the $28 billion annual savings estimate will materialize — that figure is an ARPA-H estimate contingent on success.
• Measured reductions in preventable deaths, hospitalizations, or adherence gains under ADVOCATE protocols — those are goals, not published outcomes yet.
• That supervisory AI plus implementation partners equal zero unsafe recommendations in production heart-failure care.

Treat this as a funded pathway and regulatory design proof with named performers — not a confirmatory clinical outcomes study. Operators should separate award headlines from authorization and from outcome claims.

Operator checklist for agentic clinical AI headlines

Use a short filter before you rewrite your care-ops or product roadmap:

1. Funded vs authorized? ADVOCATE funds a path to an FDA package in 24 months. Ask which milestone is live today versus which is a deadline.
2. Who owns clinical authority? UpDoc’s rules layer, Atman’s decision engine, and Tempus’s Olivia extension all imply different failure owners — name yours before agents escalate care.
3. Where does supervision live? Stanford’s TA2 story is continuous monitoring after deployment. Demand inspectable rationales and out-of-distribution handlers, not a dashboard slide.
4. What is the EHR reality? Duke and Kaiser paths span Epic and Cerner/Oracle. Map connectors, shadow-mode gates, and rural access constraints before you promise 24/7 coverage.
5. What is measurable? Preventable hospitalizations, titration delays, adherence, escalation appropriateness — named baselines before and after. Do not treat ARPA-H’s $28B estimate as your internal ROI model.

At BuildBrain, we treat agentic clinical AI as an architecture and governance pressure test: decision rights, evaluation gates, and a named owner of failure before agents touch patients or workpapers.

Talk to Ada for a free diagnostic conversation and report on where your AI stack has demos but no confirmatory design — then decide whether a paid architecture audit is next. Start on buildbrain.systems.

Bottom line

ARPA-H put real money and named teams behind ADVOCATE: patient-facing heart-failure agents (Atman Health, Tempus AI, UpDoc), Stanford supervisory AI, Duke and Kaiser Permanente implementation, JHU/APL evaluation, and FDA Digital Health Center of Excellence engagement — with an FDA authorization package due within 24 months of award.

Demand a clinical AI path you can govern: funded milestones, package deadlines vs authorizations, named clinical owners, EHR constraints, and outcome metrics — not another “AI care team” headline without a failure owner.

If you want a free report from a live diagnostic conversation before any paid audit, talk to Ada on buildbrain.systems.

Disclaimer: This article summarizes the public ARPA-H ADVOCATE announcement and is for general informational purposes only. It does not constitute medical, clinical, regulatory, legal, tax, financial, investment, or compliance advice. BuildBrain Systems / BuildBrain is not a healthcare provider, medical device manufacturer, law firm, accounting firm, or registered investment adviser. ADVOCATE technologies described are investigational clinical AI under a funded research program; an FDA authorization package deadline is not FDA authorization. Cost-savings estimates are ARPA-H projections contingent on program success. Product features, performer roles, and regulatory claims reflect sources at the time of writing and may change. Readers should verify current information independently and consult qualified professionals regarding obligations specific to their industry, jurisdiction, and circumstances—including applicable federal, state and local requirements. Nothing in this article is an endorsement of any specific AI product, model, health system, performer, or regulatory pathway.